Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Neuroone Medical Technologies (NMTC) Invested Capital (2016 - 2026)

Neuroone Medical Technologies filings provide 15 years of Invested Capital readings, the most recent being $5.4 million for Q1 2026.

  • On a quarterly basis, Invested Capital rose 377.29% to $5.4 million in Q1 2026 year-over-year; TTM through Mar 2026 was $5.4 million, a 377.29% increase, with the full-year FY2025 number at $7.1 million, up 760.39% from a year prior.
  • Invested Capital hit $5.4 million in Q1 2026 for Neuroone Medical Technologies, down from $6.4 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $13.1 million in Q1 2022 to a low of $822013.0 in Q3 2024.
  • Median Invested Capital over the past 5 years was $5.5 million (2023), compared with a mean of $5.9 million.
  • Biggest five-year swings in Invested Capital: crashed 87.11% in 2024 and later soared 760.39% in 2025.
  • Neuroone Medical Technologies' Invested Capital stood at $8.2 million in 2022, then crashed by 45.93% to $4.4 million in 2023, then crashed by 33.56% to $2.9 million in 2024, then skyrocketed by 118.1% to $6.4 million in 2025, then decreased by 16.06% to $5.4 million in 2026.
  • The last three reported values for Invested Capital were $5.4 million (Q1 2026), $6.4 million (Q4 2025), and $7.1 million (Q3 2025) per Business Quant data.